Compare DexCom, Inc. (DXCM) vs Zillow Group Inc Class C (Z) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Zillow Group (Z) trades at $33.83, up 6.18% today, with a bullish technical signal but mixed indicators. The company shows improving fundamentals, with revenue growing to $2.58B in 2025 and a return to profitability (net income of $23M). However, a high P/E ratio of 135.38 indicates premium valuation, and negative net cash flow persists. Recent news highlights multiple securities class action lawsuits alleging fraud related to an anticompetitive agreement, creating significant headline risk.

The outlook is cautious; while analyst consensus is a Buy with a $57.67 price target implying substantial upside, near-term sentiment is pressured by litigation. The key opportunity lies in continued execution on revenue growth and margin expansion, but investors face elevated risks from legal proceedings and the stock's high valuation multiples.